Linked Life Data

20056487

Source:http://linkedlifedata.com/resource/pubmed/id/20056487

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2010-2-23
pubmed:abstractText
The emergence of artemisinin resistance could adversely impact the current strategy for malaria treatment; thus, new drugs are urgently needed. A possible approach to developing new antimalarials is to find new uses for old drugs. Some anticancer agents such as methotrexate and trimetrexate are active against malaria. However, they are commonly perceived to be toxic and thus not suitable for malaria treatment. In this opinion article, we examine how the toxicity of anticancer agents is just a matter of dose or 'only dose makes the poison', as coined in Paracelsus' law. Thus, the opportunity exists to discover new antimalarials using the anticancer pharmacopoeia.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1471-5007
pubmed:author
pubmed:copyrightInfo
Copyright 2009 Elsevier Ltd. All rights reserved.
pubmed:issnType
Electronic
pubmed:volume
26
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
125-9
pubmed:dateRevised
2010-9-21
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Anticancer agents against malaria: time to revisit?
pubmed:affiliation
Kenya Medical Research Institute (KEMRI)/Wellcome Trust Collaborative Research Programme, Kilifi, Kenya. anzila@kilifi.kemri-wellcome.org
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't